Research shows how 'Mallard' dye fills need for speedFebruary 15, 2013
Researchers have developed a dye which provides a quick and accurate method of checking heparin levels in the blood.
Heparin is an important anti-coagulant which has a significant role in major surgery. The scientists in the Department of Chemistry at York have used inspiration from biological systems to allow the dye to bind heparin even in highly competitive human serum.
In the laboratory, they have modified existing dyes which previously could not bind with heparin successfully under these challenging conditions. The modified dye, which has excellent sensing capacity for heparin pinpoints the anti-coagulant's level in human serum and has the potential to work more quickly than existing clinical methods for doing this.
The research, which was funded by the Biotechnology and Biological Sciences Research Council, is published in the Journal of the American Chemical Society.
Because the dye can rapidly detect heparin levels, the scientists have named it 'Mallard Blue'. It is the same shade as the livery of the A4 Pacific Mallard, which holds the world speed record for a steam locomotive, and is now preserved at the National Railway Museum in York.
Professor Dave Smith, of the Department of Chemistry at York who led the research said: "Our new dye allows the quantification of heparin in serum at clinically relevant levels and is the best in class for this application in terms of its ability to bind heparin strongly under really competitive biological conditions, and may improve on the currently used systems.
"We have named the dye 'Mallard Blue', after the record-breaking steam train, 'Mallard' which is housed in the railway museum here at York. Our dye is the same colour as the locomotive, and we believe it is similarly ground-breaking in its performance."
The York researchers worked with a team led by Sabrina Pricl at the University of Trieste who used high-level computer modelling to understand precisely how Mallard Blue binds to heparin so strongly.
The next stage in this research would involve the incorporation of this new dye into a device for simple bedside read-out of heparin levels in blood.
University of York
Related Heparin Current Events and Heparin News Articles
Heparin more effective than bivalirudin in patients during emergency heart procedure
In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack.
Repeated hUCB injections may improve prognosis of children with deadly inherited disorder
New insight has been gained into treating an inherited disorder that creates serious neurological and behavioral disabilities in children and usually leads to death in the teen years.
Antidote can deactivate new form of heparin
Low-molecular-weight heparin is commonly used in surgeries to prevent dangerous blood clots. But when patients experience the other extreme - uncontrolled bleeding - in response to low-molecular-weight heparin, there is no antidote.
A new treatment for heart attack will soon be available for emergency teams and the emergency ambulance
A new strategy for emergency anticoagulant treatment for patients with acute myocardial infarction has been put in place by a team led by Philippe-Gabriel Steg at Inserm Unit 698 (Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling), at Hôpital Bichat, AP-HP, Université Paris Diderot).
Study finds pre-hospital administration of bivalirudin substantially improves outcomes compared to heparin in heart attack patients
According to a new study, administering the blood thinner bivalirudin to patients experiencing an ST-elevation myocardial infarction (STEMI, the most serious form of a heart attack) in a pre-hospital setting can reduce the risk of death and major bleeding complications compared to heparin with optional use of glycoprotein IIb/IIIa inhibitors.
Research uncovers potential preventive for central line infection
A team of researchers at Cincinnati Children's Hospital Medical Center has developed an antibody that could prevent Candida infections that often afflict hospitalized patients who receive central lines.
Nutritional values established in 3 new, high-energy protein ingredients fed to weanling pigs
The use of soybean meal in diets fed to weanling pigs is limited due to the presence of anti-nutritional factors that young pigs can't tolerate.
New chemical approach to treat Alzheimer's
Scientists at the University of Liverpool and Callaghan Innovation in New Zealand have developed a new chemical approach to help harness the natural ability of complex sugars to treat Alzheimer's disease.
Registry questions superiority of bivalirudin over heparin
Results from a large observational study reported at EuroPCR 2013 today question whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality in patients with non-ST segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI).
Stillbirth or Pre-Term Birth Outcomes Linked to Elevated Risk of Blood Clots After Pregnancy
Newly identified pregnancy-related events, such as stillbirth or pre-term birth, may dramatically increase a woman's risk of developing a potentially deadly blood clot immediately after pregnancy, according to the results of a large, population-based study published online today in Blood, the Journal of the American Society of Hematology (ASH).
More Heparin Current Events and Heparin News Articles